Six Sigma in Drug Discovery: Part One - Are Chemists Too Individual?

Overview

• Author: Derek Lowe
• Publication Date: April 10, 2021
• Source: Science | AAAS
• Main Focus: Examination of Lean Six Sigma application in drug discovery and the potential impact on chemists' work styles.

Key Points

Lean Six Sigma in Drug Discovery

• Originated from a 2009 AstraZeneca paper.
• Focuses on efficiency and reducing time loss.
• Traditionally viewed by Derek Lowe as overly managerial and buzzword-driven.

AstraZeneca's Approach

• Lead Optimization: Recommends submitting lead-optimization compounds in 30-35 mg batches to save time in the long run.
• Chemistry Team Dynamics:
  • Traditional: Chemists work independently on multiple compounds.
  • New Approach: Encourages cooperative team work with visual planning systems.
  • Objectives: Reduce lead times, monitor progress, and identify issues more easily.

Controversy and Discussion

• Debate on whether independent or team-based approaches yield better productivity.
• Questions raised about the practical implementation and actual success of AstraZeneca's methods.

Reflections

• Historical organization of chemistry work as individual-based may stem from academic training.
• The potential benefit of team collaboration in reducing synthesis lead times.

Discussion Points

• Is individual work style in chemistry detrimental to productivity?
• Can AstraZeneca's proposed changes be effectively implemented industry-wide?
• Potential for broader adoption of Six Sigma practices in pharmaceutical industries.

Personal Insights

• Derek Lowe's skepticism of Six Sigma's efficacy outside of manufacturing settings.
• Open to persuasion by evidence if the changes prove effective.

Conclusion

Discussion remains open about the viability and success of shifting chemists' work styles in drug discovery towards a more collaborative approach driven by Lean Six Sigma methodologies.